Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

Nimotuzumab:

  • Daiichi Sankyo, CIMYM's licensee for nimotuzumab in Japan, previously initiated a randomized trial with the EGFR-targeting humanized monoclonal antibody in second line gastric cancer together with Kuhnil Pharma Co. Ltd., CIMYM's licensee in Korea, which they report completed recruitment in calendar 2009. Daiichi also launched a Phase II trial in first-line NSCLC for which YM has been advised that recruitment has been completed. Reports on both trials are expected during the first half of calendar 2011 as data mature. Oncoscience AG (OSAG), CIMYM's licensee for Europe, reported safety data from a Phase III trial in adult glioma patients at ASCO 2010 and OSAG continues to recruit patients into a Phase IIb/III trial in pancreatic cancer patients. We are now advised by OSAG that data from the adult glioma trial may be released in the first half of 2011.

  • YM's two randomized, Phase II, double-blind trials of nimotuzumab (for brain metastasis from non-small cell lung cancer and for palliative stage NSCLC) are lagging recruitment targets and consequently these programs are under review as the Company focuses support on the more advanced trials involving Daiichi Sankyo which have the prospect of earlier registration trial initiation. YM's Phase II, second-line, single-arm study in children with progressive diffuse intrinsic pontine glioma (DIPG) has concluded recruitment at multiple sites in the US, Canada, and Israel and should report results prior to the end of calendar 2010.
  • CYT997:

  • Phase I clinical trial results for CYT997 were published in the premier cancer journal, the British Journal of Cancer, demonstrating that CYT997 was well tolerated at doses that were associated with evidence of vascular disruption in tumors. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity currently in a Phase II trial for glioblastoma
    '/>"/>

  • SOURCE YM BioSciences Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
    2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
    3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
    4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
    6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
    8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
    9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
    10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
    11. Cell Biosciences to Acquire Convergent Bioscience
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... September 23, 2014 Dr. Williams says, ... book on healthcare offers a three phase process that ... healthcare delivery system that would go far beyond anything ... regarding the delivery of healthcare.” , “Every effort to ... failed to provide discernable progress throughout that system because ...
    (Date:9/22/2014)... were treated with a statin in the hospital after ... to survive than those who were not, according to ... This study was conducted by the same researchers who ... improve survival in victims of ischemic stroke., Ischemic stroke ... blood vessel that blocks blood from reaching areas of ...
    (Date:9/22/2014)... LEGO-like components developed by researchers at the USC ... to build a 3-D microfluidic system quickly and ... hand. , Microfluidic systems are used in ... precisely manipulate small volumes of fluids for use ... pathogen detection, clinical diagnostic testing, and synthetic chemistry. ...
    (Date:9/22/2014)... developed a unique nanoscale device that for the ... discovery could have major implications for creating faster ... communication. , The research paper by University of ... Li and his graduate student Huan Li has ... October issue of Nature Nanotechnology . , ...
    Breaking Biology Technology:Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Engineers show light can play seesaw at the nanoscale 2
    ... , , , ... (Medical College), a private medical school with more than 1,100 physicians, ... (SRM) solution to track, manage and report adverse and near-miss events, ... Event Manager (EM) and Claims Manager (CM) modules, part of the ...
    ... ... Room To Share Due Diligence Documents , ... Los Gatos, CA (PRWEB) September 16, 2009 -- Pandesa ... a number of pharmaceutical, biopharmaceutical and biotech research and development companies worldwide, to securely ...
    ... AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: ... endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, ... licensee for perifosine in the North American market, has ... Food and Drug Administration (FDA) for the treatment of ...
    Cached Biology Technology:The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 2Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering 3AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3
    (Date:9/23/2014)... Research and Markets  has announced the ... Opportunities, 2019" report to their offering. ... security and protection in private as well as government ... government is focusing on using biometric systems to store ... IDs that are of crucial importance to the country. ...
    (Date:9/23/2014)... Newest Market IPO,s and ... for significant investor attention with news concerning shareholder updates and ... are: NXT-ID, Inc. (NASDAQ: NXTD ), Alibaba Group ... MBLY ), GoPro, Inc. (NASDAQ: GPRO ... Inc. (NASDAQ: NXTD ) recently completed an essential ...
    (Date:9/23/2014)... parasitic DNA fragments called "jumping genes" that insert themselves ... And that phenomenon can result in age-related diseases such ... now report that the "jumping genes" in mice become ... stops keeping them in check in order to take ... today in Nature Communications , Professor of Biology ...
    Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
    ... therapies similar to those used for HIV patients may be the ... the University of Leeds. A study of a protein called ... the protein between virus strains - known as genotypes - ... function. The p7 protein assists the spread of HCV ...
    ... U.S. Department of Energy Joint Genome Institute (DOE JGI) ... (Glycine max) genetic code, making it widely available to ... one of the world,s most valuable plant commodities. ... world,s edible protein, but also is an emerging feedstock ...
    ... DECEMBER 8, 2008 Animal feeding operations are an ... and carbon dioxideknown greenhouse gases. Recent inventories suggest ... global methane emissions. As a consequence, greenhouse gas ... the development and sustainability of animal production and ...
    Cached Biology News:Leeds research points to new therapy for hepatitis C treatment 2DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Oil spray reduces greenhouse gas emissions from pig finishing barns 2
    Defender against cell death 1...
    Request Info...
    ... Hypothetical protein FLJ20644, likely ortholog of ... Protein Accession #: NP_060387.1 gi ... Definition: chromosome 14 open reading frame ... gene g4-1 [Homo sapiens] Locus ...
    1/4" to 1/8" Adapter for Reflectance Probe Holder...
    Biology Products: